Lipid nanoparticle-delivered mRNA IL-12 remodels the tumor microenvironment to potentiate neoantigen cancer vaccine efficacy

Personalized cancer vaccines (PCVs) targeting tumor-specific neoantigens have emerged as a promising strategy for cancer immunotherapy; however, their clinical efficacy remains limited by insufficient immunogenicity and inadequate remodeling of the tumor microenvironment (TME). To overcome these limitations, we investigated whether lipid nanoparticle (LNP)-based cytokine mRNA delivery could function as an immune modulator to enhance neoantigen vaccine efficacy. We evaluated the combinatorial effects of mRNA-based cytokines (GM-CSF, IL-12, and IL-15) with MHC class I- and class II-restricted neoantigen vaccines in a syngeneic MC38 colon cancer model. Following peritumoral administration, LNP-mediated mRNA delivery enabled localized cytokine expression, facilitating enhanced intratumoral immune activation while limiting systemic exposure. Among the candidates, mRNA-encoded IL-12 provided the greatest therapeutic benefit when combined with neoantigen vaccination, leading to robust tumor suppression and prolonged survival in both subcutaneous and peritoneal metastasis models. Mechanistically, IL-12 markedly enhanced MHC class II-restricted CD4⁺ T cell responses, as evidenced by increased IFN-γ and TNF-α production. Enhanced CD8⁺ T cell responses were also observed within the tumor microenvironment. These changes were accompanied by increased antigen-presenting cell activation, including dendritic cells and macrophages. Furthermore, IL-12-based combination therapy reshaped the TME by increasing tumor-infiltrating lymphocytes and effector T cells while reducing immunosuppressive regulatory T cells, thereby establishing a more immunostimulatory tumor milieu. Collectively, our findings demonstrate that LNP-mediated mRNA cytokine delivery enables effective in situ immune modulation, providing a biomaterial-based strategy to enhance neoantigen vaccine efficacy through controlled cytokine exposure and TME remodeling.

Authors

Institutions

Publication Details

Journal
Journal of Nanobiotechnology
Published
2026-11-14
DOI
https://doi.org/10.1186/s12951-026-05252-x
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Lipid nanoparticle-delivered mRNA IL-12 remodels the tumor microenvironment to potentiate neoantigen cancer vaccine efficacy

Dahyeon Ha, Subin Yoon, Yu‐Sun Lee, Sohee Jo et al.
Journal of Nanobiotechnology
Immunotherapy and Immune Responses
article

Lipid nanoparticle-delivered mRNA IL-12 remodels the tumor microenvironment to potentiate neoantigen cancer vaccine efficacy

Dahyeon Ha, Subin Yoon, Yu‐Sun Lee, Sohee Jo, Jung Sik Lim, Ayoung Oh, Huijeong Choi, Min-Ho Kang, Jisun Lee, Seongje Cho, Jungmin Kim, Sowon Lee, Jae-Hwan Nam, Sang-In Park, Yeeun Lee, Seonghyun Lee, Woori Kwak
article en

Abstract

Personalized cancer vaccines (PCVs) targeting tumor-specific neoantigens have emerged as a promising strategy for cancer immunotherapy; however, their clinical efficacy remains limited by insufficient immunogenicity and inadequate remodeling of the tumor microenvironment (TME). To overcome these limitations, we investigated whether lipid nanoparticle (LNP)-based cytokine mRNA delivery could function as an immune modulator to enhance neoantigen vaccine efficacy. We evaluated the combinatorial effects of mRNA-based cytokines (GM-CSF, IL-12, and IL-15) with MHC class I- and class II-restricted neoantigen vaccines in a syngeneic MC38 colon cancer model. Following peritumoral administration, LNP-mediated mRNA delivery enabled localized cytokine expression, facilitating enhanced intratumoral immune activation while limiting systemic exposure. Among the candidates, mRNA-encoded IL-12 provided the greatest therapeutic benefit when combined with neoantigen vaccination, leading to robust tumor suppression and prolonged survival in both subcutaneous and peritoneal metastasis models. Mechanistically, IL-12 markedly enhanced MHC class II-restricted CD4⁺ T cell responses, as evidenced by increased IFN-γ and TNF-α production. Enhanced CD8⁺ T cell responses were also observed within the tumor microenvironment. These changes were accompanied by increased antigen-presenting cell activation, including dendritic cells and macrophages. Furthermore, IL-12-based combination therapy reshaped the TME by increasing tumor-infiltrating lymphocytes and effector T cells while reducing immunosuppressive regulatory T cells, thereby establishing a more immunostimulatory tumor milieu. Collectively, our findings demonstrate that LNP-mediated mRNA cytokine delivery enables effective in situ immune modulation, providing a biomaterial-based strategy to enhance neoantigen vaccine efficacy through controlled cytokine exposure and TME remodeling.

Journal of Nanobiotechnology
Daegu Haany University (KR), The Catholic University of Korea Bucheon St. Mary's Hospital (KR), Korea Disease Control and Prevention Agency (KR), Catholic University of Korea (KR)
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon